Affordable Access

[Safety and efficacy of movalis injected into trigger points in lumbago-ischialgia syndrome].

Authors
Type
Published Article
Journal
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Publication Date
Volume
108
Issue
9
Pages
41–44
Identifiers
PMID: 18833170
Source
Medline

Abstract

Efficacy and safety of movalis (meloxicam) injected into trigger points of 94 patients with vertebrogenic lumbago-ischialgia syndrome have been assessed. Patients have been stratified into 3 randomized groups: the first group received 3 injections of movalis into trigger points with the following administration of tablets (15 mg per day); 2nd group received - 3 intramuscular injection movalis with the following administration of tablets (15 mg per day); 3nd - was control. Treatment efficacy has been assessed with the Visual-Analogous scale, a five-point scale for assessment of vertebroneurological symptoms, the Oswestry Disability Index, the McGill Pain Questionnaire, stimulating ENMG. Patients treated with movalis injections into trigger points and intramuscular had no local side-effects. The analgesic effect was more pronounced after three injections into trigger points compared to the intramuscular injection. The efficacy of treatment was the highest in the first group (75,6%) comparing to the 2nd (64,3%) and the 3rd (33,3%) ones.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments